Other Events ·
20/20 Biolabs, Inc. received a notification from Nasdaq on September 3, 2026, indicating non-compliance with the…
AIDX20/20 Biolabs, Inc.
20/20 Biolabs, Inc. received a notification from Nasdaq on September 3, 2026, indicating non-compliance with the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1). The company's Form 10-Q for the period ended June 30, 2026, reported stockholders’ equity of $1,620,700. Nasdaq has granted the company 45 calendar days to submit a plan to regain compliance; if accepted, an extension of up to 180 calendar days may be granted. Failure to comply by January 13, 2027, would disqualify the company from a second compliance period for its previously cited bid price deficiency. The company operates in the biotechnology industry, focusing on laboratory diagnostics and research products.